JPRN-jRCTs031180152已完成未知
The safety and efficacy of tocilizumab in patients with neuromyelitis optica: Multicenter study - Tocilizumab in patients with neuromyelitis optica
Yamamura Takashi0 个研究点目标入组 20 人开始时间: 2019年2月25日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
This is an exploratory clinical study investigating the safety profiles and efficacy of tocilizumab for refractory anti-AQP4-Ab+ neuromyelitis optica patients. In total, 20 patients were enrolled. The safety profiles included 16 infections, mostly mild and there were no unexpected severe adverse events. Clinical efficacy were apparent with significant reduction of annual relapse rates after tocilizumab treatment.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 65age old（—）
- 性别
- All
入选标准
- •Diagnosis of neuromyelitis optica (NMO), as defined by 2006 criteria published in NEUROLOGY vol. 66 or NMO seropositive spectrum disorder (recurrent optic neuritis or longitudinally extensive transverse myelitis). All patients must be anti-aquaporin 4 antibody seropositive.
- •Patients with intractable NMO who are resistant to the standard therapy or experiencing sever adverse reactions of the current therapy.
- •History of at least one relapse during the 1 year prior to initiation of this study.
- •Provision of written informed consent to participate in this study.
排除标准
- •1) Patients with severe infection
- •tuberculosis, pneumocystis carinii pneumonia, nontuberculous mycobacterial infection (diagnosed by tuberculin test, beta-D glucan,chest X-ray)
- •When the tuberculin test shows intermediate or strong positivity, or the patients have a clinical history of contact with a patient with tuberculosis, isoniazid or rifampicin at a dose of 300 mg once daily for 6 to 9 months with pyridoxal at a dose of 10mg once daily initiated 3 weeks prior to tocilizumab.
- •Immunocompromised host
- •2) hepatitis B (positivity for HBS Ag and HBC Ab, hepatitis C (positivity for HCV Ab), or chronic active EB virus infection.
- •Patients with a history of tuberculosis infection or patients with pleural thickness or old tuberculin in chest X-ray.
- •3) Patients with a history of hypersensitivity to this drug.
- •4) Patients with a history of intestinal diverticulum.
- •5) Patients with interstitial pneumonitis.
- •6) Patients with leukopenia (white blood cell number less than 4000/mm3), lymphopenia (lymphocyte number less than 500/mm3) or seropositivity for beta-D-glucan in peripheral blood.
- •7) Pregnant women or patients with possible pregnancy.
- •8) Patients aged older than 20 and younger than 66 years.
- •9) Patients with a history of allergic reaction to tocilizumab.
- •10) Patients who cannot provide consent to participate in this study by themselves.
- •11) Patients whose EDSS are more than 7.
研究者
相似试验
终止
2 期
Tocilizumab for the Treatment of Refractory Behcet's UveitisBehcet SyndromeUveitisNCT03554161Wenjie Zheng3
已完成
不适用
The efficacy and safety of tocilizumab in patients with neuromyelitis opticaneuromyelitis opticaJPRN-UMIN000022201Department of Neurology, Shimane University Hospital3
已完成
不适用
Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Participants With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Non-Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) and/or Anti-tumor Necrosis Factor (Anti-TNF) TherapyRheumatoid ArthritisNCT01362062Hoffmann-La Roche110
已完成
不适用
The safety and efficacy of tocilizumab in patients with neuromyelitis optica: Multicenter Studyneuromyelitis opticaJPRN-UMIN000007866Department of Immunology, National Institute of Neuroscience, NCNP15
已完成
不适用
The safety and efficacy of tocilizumab in patients with neuromyelitis opticaneuromyelitis opticaJPRN-UMIN000005889Department of Immunology, National Institute of Neuroscience, NCNP3